Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies-Reference-Cited by-同舟云学术

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies

Published:2016-08 Issue:4 Volume:26 Page:413-416
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Hwang Shelley J.E.,Carlos Giuliana,Chou Shaun,Wakade Deepal,Carlino Matteo S.,Fernandez-Penas Pablo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference17 articles.

1. Immune checkpoint inhibitors: therapeutic advances in melanoma;Marquez-Rodas;Ann Transl Med,2015

2. Cancer: antitumour immunity gets a boost;Wolchok;Nature,2014

3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012

4. Cutaneous adverse events of anti-programmed cell death 1 therapy in patients with metastatic melanoma: a single-institution cohort;Hwang;J Am Acad Dermatol,2016

5. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab;Carlos;Melanoma Res,2015

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy;Molecular Therapy;2024-08

2. Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival;Oral Diseases;2024-06-27

3. Immune Checkpoint Inhibition;Side Effects of Cancer Therapy;2024

4. Immune Checkpoint Inhibition;Side Effects of Cancer Therapy;2023-10-31

5. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid;Frontiers in Oncology;2023-03-03